A Study of the Effectiveness of Rifaprim in Chronic prostatitis Caused Mainly by Staphylococcus Aureus

Publisher Website
Google Scholar
Abstract
Rifampicin plus trimethoprim (rifaprim) was used to treat 20 patients with chronic prostatitis in exacerbation: 11 received 2 tablets at bedtime for 15 days followed by 1 tablet at bedtime for another 105 days; 9 received 1 tablet in the morning and 2 tablets at bedtime for 15 days, then 2 tablets at bedtime for 15 days followed by 1 tablet at bedtime for another 90 days. All patients had an enlarged tender prostate and all but 2 were symptomatic. In 10 patients, previous treatment, including co-trimoxazole in 5, had failed. Cultures of the expressed prostatic secretions yielded S. aureus in 17 patients and gram-negative microorganisms in 3. At the end of treatment, 6 of 11 patients given the lower dosage were cured clinically and bacteriologically compared to 8 of 9 given the higher dosage. After 2-3 yr of followup, 5 of 9 patients in the 1st group and all 7 in the 2nd group had not suffered relapse. Thus, rifaprim is a potent drug in the treatment of chronic prostatitis caused mainly by S. aureus. The promptness of therapeutic response and the cure rate (at the end of treatment and after .gtoreq. 2 yr of followup) favor the higher drug dosage.